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The World of Placebos
BY ZACHARY WANG ’20
Introduction
The Placebo Effect is a fascinating but 
poorly understood mystery of medicine and 
human biology. Its workings continue to 
surprise scientists and patients everywhere. 
This is a brief introduction to the placebo effect 
from its early roots to current issues and new 
discoveries in the field.
Then...
The First “Placebo”
In the 16th century, religious authorities 
conceived of a unique way to test whether or 
not someone was actually possessed (Lemoine, 
2015). When individuals showed questionable 
signs of diabolical possession, they would be 
given false relics. If the “possessed” acted as 
if they were real, the healer would be able to 
deduce that the seizures or other symptoms 
were either fake, or the result of an overactive 
imagination. In this manner, one of the earliest 
documented instances of using an ineffectual 
replica of a real treatment was conceived.
The First “Actual” Placebo
In 1752, James Lind, a doctor in the Royal 
Navy, published “A Treatise of the Scurvy” in 
which he unknowingly performed the first 
recorded use of placebo groups (Lemoine, 2015). 
The inventor of what would one day be called 
a “controlled trial,” Lind selected 12 sailors 
suffering from scurvy and divided them into 
groups of two, assigning each group one of six 
different treatments. The groups received either 
cider, an elixir of vitriol (sulfuric acid), vinegar, 
seawater, lemons and oranges, and, lastly, a 
mixture of garlic, mustard, and horseradish 
root, respectively. The sailors in the lemons and 
oranges group healed in days as well as those 
in the cider group, though not as quickly. The 
other four groups were the placebo groups, and 
their treatment proved to be fatal. Ethically, 
one would hope that Dr. Lind did not intend to 
kill the other four groups, given the substances 
administered were considered therapeutic at the 
time, though not for the treatment of scurvy.
Medicine Embraces the Placebo
It took until 1785 for the term “placebo” 
to first show up in the Motherby’s New 
Medical Dictionary, where it is defined as “a 
commonplace medication or method” (Lemoine, 
2015). The word “commonplace” should 
probably be taken to mean “overused and 
unimportant.” The first time the word appeared 
in its modern form was 1958, after the advent of 
double-blind controlled trials with randomized 
assignment. From this point on, placebos gained 
scientific respectability in contrast to the earlier 
connotation of pseudoscience.
The Discovery of the Placebo Effect
PSYCHOLOGY
Figure 1: Drugs earlier 
approved by the FDA (such as 
Prozac) are now failing further 
tests due to the placebo effect.
 
Source: Wikimedia Commons 
(Credit: Tom Varco)
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In a famous article published in the Journal 
of the American Medical Association in 1955, 
using data from 15 studies encompassing 1082 
patients with varied types and degrees of 
pain, Henry K. Beecher showed that a placebo 
analgesic is effective, on average, in 35.2% of 
cases, though individual studies ranged from 4% 
to 86% efficacy (Beecher, 2015). Pain that was 
least natural in origin, i.e. experimental pain 
triggered in a laboratory on healthy subjects, 
was least responsive to placebos whereas 
natural pain, like chest pain, was most sensitive 
to placebos. Since then, countless publications 
have quantified the effectiveness of placebos 
and the existence and importance of the 
placebo effect, varying with the patient’s and 
physician’s awareness of the placebo. Thus, the 
placebo effect gained fame as an impressive feat 
of human biology and legitimacy in the eyes of 
the medical community. 
...and Now
The Ailing Pharmaceutical Industry
The Problem:
Merck was in trouble. In 2002, the 
pharmaceutical giant was rapidly falling behind 
its competitors in sales (Silberman, 2009). To 
make matters worse, patents on five best-selling 
drugs were about to expire, allowing cheaper 
generics to flood the market. The company had 
not introduced a truly new product in three 
years, and its stock was plummeting. In an 
interview, Edward Scolnick, Merck’s research 
director at the time, described his plan to bring 
Merck back to the top. Fundamental to this 
strategy was a new focus on antidepressants, a 
field where Merck had previously lagged behind 
its competitors who were making some of the 
most profitable drugs such as Zoloft, Prozac, 
and Xanax in the world (Grohol, 2016). This 
plan hinged on an experimental antidepressant 
codenamed MK-869. And though still in clinical 
trials, it was shaping up to be a blessing to Merck 
and its leadership. The drug exploited human 
brain chemistry in brilliant and innovative ways 
with little to no side effects. It tested brilliantly 
early on, and Merck representatives showed 
off its amazing potential at a meeting of 300 
securities analysts (Silberman, 2009).
Though doing well on the surface, MK-869 
was starting to falter (Drugs in R & D, 2002). 
Although many test subjects felt that the drug 
lifted their sense of hopelessness and anxiety, 
nearly the same number of subjects did so as 
well with a placebo. Thus, Merck’s foray into 
antidepressants failed. In further testing, MK-
869 proved to be no more effective than placebos.
Merck’s MK-869 wasn’t the only highly 
anticipated medical breakthrough undone by 
the placebo effect (McGoey, 2010). From 2001 
to 2006, the percentage of new products pulled 
from development after Phase II trials, where 
they are first tested against placebos, shot up 
20%. Failure in the more extensive Phase III trials 
rose by 11%. So despite unprecedented amounts 
of investment in research and development, 
the FDA only approved 19 original remedies 
in 2007—the fewest since 1983—and 24 in 2008. 
Half of all medications that fail in late-stage 
trials are undone due to their inability to beat 
out a simple sugar pill.
The Consequences:
What’s the fallout of this phenomenon? 
Fewer new medicines are becoming available 
to suffering patients and further financial 
woes troubling the pharmaceutical industry 
(Silberman, 2009). In November of 2009, a new 
type of gene therapy for Parkinson’s disease, 
championed by the Michael J. Fox Foundation, 
was abruptly withdrawn from Phase II trials 
after unexpectedly tanking against placebo. A 
stem-cell startup called Osiris Therapeutics got 
a drubbing on Wall Street that March, when it 
suspended trials of its pill for Crohn’s disease, 
an intestinal ailment, citing an “unusually high” 
response to placebo. Two days later, Eli Lilly 
broke off testing of a much-touted new drug for 
schizophrenia when volunteers showed double 
the expected level of placebo response.
And it’s not just new drugs that are failing 
against placebos. Products that have been 
available for decades, like Prozac, are now failing 
in more recent follow-up testing (McGoey, 
2010). If these same drugs were being developed 
now, they may not pass FDA approval. 
According to drug developers, it’s not that 
the old medications are getting weaker, but that 
the placebo effect, a beneficial effect produced 
by an inert placebo drug or treatment, is getting 
stronger (Spiegel, 2010). And it appears that the 
placebo effect is not just becoming stronger, but 
also increasing in breadth.
Effectiveness of Open Label Placebos
Linda Buonanno had suffered 15 years of 
“Pain that was least 
natural in origin, 
i.e. experimental 
pain triggered in 
a laboratory on 
healthy subjects, 
was least responsive 
to placebos whereas 
natural pain, like 
chest pain, was 
most sensitive to 
placebos.”
Figure 2: Pharmaceutical 
companies like Merck are 
facing the consequences of 
the increasingly powerful 
placebo effect, as well as their 
customers.
 
Source: Wikimedia Commons 
(Credit: Merck KgaA)
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intense cramps, bloating, diarrhea and pain she 
describes as “worse than labor” (Fleming, 2017). 
She was willing to try anything to get relief 
from her irritable bowel syndrome (IBS) and 
leapt at the chance to take part in a trial of an 
experimental new therapy. Her hope turned to 
disappointment, however, when the researcher 
handed her a bottle of capsules he described 
as placebos containing no active ingredients. 
Nonetheless, she took the pills twice daily. 
Four days later, her symptoms all but vanished. 
“I know it sounds crazy,” says Buonanno, of 
Methuen, Massachusetts. “I felt fantastic. I knew 
they were just sugar pills, but I was able to go 
out dancing and see my friends again.” Placebos 
have a reputation problem. It is widely believed 
they are only effective when those taking them 
are deceived into thinking they are taking real 
drugs. However, prescribing dummy or fake 
treatments is unethical. Yet in Buonanno’s case 
there was no deception and she experienced 
substantial relief. And she is not alone.
On the 27th of April 2017, clinical 
epidemiologist Dr. Jeremy Howick and a group 
of other scientists working out of the University 
of Oxford, Harvard Medical School, and multiple 
psychology departments published the Effects 
of placebos without deception compared with no 
treatment (Charlesworth, 2017). A meta-analysis 
and review of five research studies covering 260 
patients, showing the effectiveness of “open-
label” placebos for a number of health issues. 
“Open-label” placebos are normal placebos, 
except that patients know that they’re placebos. 
Howick writes “[normally] we have to believe 
they are “real” treatments, which means the 
doctor would have to lie to us and say that the 
placebo was actually a real treatment. Or, in the 
case of a clinical trial, that it might be a real 
treatment. After all, if a doctor handed you a pill 
and said, ‘this is just a sugar pill’, you’d probably 
assume it wouldn’t work. But sometimes our 
assumptions are mistaken” (2017). Previously, 
the belief was that the placebo effect only 
worked when patients believed they were 
taking real medicine. With this study, this is no 
longer necessarily the case.
According to Howick, “the history of open-
label placebos can be traced back to at least 
1965 when Baltimore doctors, Lee Park and Uno 
Covi, gave open placebos to 15 neurotic patients. 
They told the patients: ‘Many people with your 
kind of condition have been helped by what are 
sometimes called sugar pills and we feel that a 
so-called sugar pill may help you too’” (2017). 
Many of the patients got better. Paradoxically, 
since these were neurotic patients, they thought 
that the doctors had lied to them and given 
them real drugs.
The first study reviewed was led by 
Professor Ted Kaptchuk, of Harvard Medical 
School, who gave 80 IBS patients, including 
Buonanno (Fleming, 2017), either no treatment 
or open-label placebo pills (Charlesworth, 
2017). He found those who took placebos for 
three weeks experienced greater improvements 
in symptoms, including less severe pain. In 
another of the studies in Howick’s review, 
“Previously, the 
belief was that 
the placebo effect 
only worked when 
patients believed 
they were taking 
real medicine. With 
this study, this is no 
longer necessarily 
the case.”
Figure 3: Pavlov’s dogs and 
their keepers. Ivan Pavlov 
demonstrated classical 
conditioning by training dogs 
to salivate by association.
Source: Wikimedia Commons 
(Credit: Wellcome Images)
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effects can benefit many patients it is probably 
unethical not to exploit them.”
The placebo effect, though already poorly 
understood and mysterious, seems to be 
evolving in strength and breadth right before 
our very eyes. A few months ago, most were 
confident that placebo effects only occurred 
when patients were unaware they were taking 
a placebo. And yet recently we learned that 
wasn’t the case. The consequences of the 
placebo effect’s “new abilities” are far-reaching 
and represent a double-edged sword. On the one 
hand, people who find no succor from presently 
available pharmaceuticals may now find relief. 
On the other hand, many people who need new, 
upcoming treatments may have their hopes 
dashed by a sudden discontinuity of research 
into a treatment. Just as our understanding 
of the placebo effect seems to be evolving, 
so is its future role in medicine. Will we find 
it to be an enemy, stealing hope away from 
anxious patients? Or will we find in it a novel 
and previously-untapped base for treatment, 
helping doctors assist suffering patients without 
harsh side-effects?
CONTACT ZACHARY WANG AT ZACHARY.Z.WANG.20@
DARTMOUTH.EDU
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chronic lower back pain patients openly given 
dummy pills to add to their existing treatments 
reported an average 30% pain reduction. In 
the three other review studies, people given 
open-label pills reported reduced symptoms 
for depression, lower back pain, and attention 
deficit hyperactivity disorder.
“Open-label placebos probably work in two 
ways,” writes Howick. “The first is expectation. 
Open-label are usually given with a positive 
suggestion: the doctor will tell the patient the 
pill is just a placebo but adds that it ‘produces 
significant improvement for patients like you’. 
This positive suggestion creates a positive 
expectation, which can activate the reward 
mechanisms in the brain and help the body 
produce its own pain-reducing substances, such 
as endorphins” (2017).
The second possible explanation is 
conditioning. Pavlov was a Russian physiologist 
who accidently discovered the phenomenon 
of classical conditioning while studying dogs’ 
gastric systems (Specter, 2014). He found that 
dogs would salivate when they heard or smelled 
food in anticipation of feeding. This is an expected 
response given the role of saliva in digestion. 
However, the dogs also began to salivate when 
events occurred which would otherwise be 
unrelated to feeding. By playing sounds to the 
dogs prior to feeding them, Pavlov showed that 
they could be conditioned to associate neutral, 
unrelated events with being fed. Just as Pavlov’s 
dogs learned to associate the sound of a bell 
with food and began salivating whenever they 
heard the bell, most of us have been conditioned 
to expect a positive outcome when a trusted 
doctor gives a treatment. “So even though we 
know a pill is a placebo,” Howick writes, “our 
bodies may react in a way that helps us heal. 
There have been several studies, including one 
in humans, showing that the immune system 
can be activated much in the same way that 
Pavlov’s dogs salivated at the mere sound of a 
bell” (2017).
Since open-label placebos have been shown 
to improve symptoms, should they be made 
available? After all, they seem to help people 
with nowhere else to go, like Buonanno, and 
have no side effects being made from sugar 
or other harmless substances. According to 
Howick, no (2017). “That may be unwise because 
it would support a pill-popping, overmedicalized 
culture.” Fortunately, the review of open-label 
placebos demonstrates something more general: 
placebo effects are real for many common 
conditions and people can use the placebo effect 
without placebo pills. Doctors who give positive 
messages and take time to communicate with 
enhanced empathy to patients can bring about 
positive benefits with or without pills. “Far from 
being unethical,” Howick says, “since placebo 
